Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study

Rulan S. Parekh, Lucy A. Meoni, Bernard G. Jaar, Stephen M. Sozio, Tariq Shafi, Gordon F. Tomaselli, Joao A. Lima, Larisa Tereshchenko, Michelle M. Estrella, Linda H L Kao

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Background: Sudden cardiac death occurs commonly in the end-stage renal disease population receiving dialysis, with 25% dying of sudden cardiac death over 5 years. Despite this high risk, surprisingly few prospective studies have studied clinical- and dialysis-related risk factors for sudden cardiac death and arrhythmic precursors of sudden cardiac death in end-stage renal disease. Methods/Design: We present a brief summary of the risk factors for arrhythmias and sudden cardiac death in persons with end-stage renal disease as the rationale for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study, a prospective cohort study of patients recently initiated on chronic hemodialysis, with the overall goal to understand arrhythmic and sudden cardiac death risk. Participants were screened for eligibility and excluded if they already had a pacemaker or an automatic implantable cardioverter defibrillator. We describe the study aims, design, and data collection of 574 incident hemodialysis participants from the Baltimore region in Maryland, U.S.A.. Participants were recruited from 27 hemodialysis units and underwent detailed clinical, dialysis and cardiovascular evaluation at baseline and follow-up. Cardiovascular phenotyping was conducted on nondialysis days with signal averaged electrocardiogram, echocardiogram, pulse wave velocity, ankle, brachial index, and cardiac computed tomography and angiography conducted at baseline. Participants were followed annually with study visits including electrocardiogram, pulse wave velocity, and ankle brachial index up to 4 years. A biorepository of serum, plasma, DNA, RNA, and nails were collected to study genetic and serologic factors associated with disease. Discussion: Studies of modifiable risk factors for sudden cardiac death will help set the stage for clinical trials to test therapies to prevent sudden cardiac death in this high-risk population.

    Original languageEnglish (US)
    JournalBMC Nephrology
    DOIs
    StateAccepted/In press - Apr 24 2015

    Fingerprint

    Sudden Cardiac Death
    Chronic Kidney Failure
    Renal Dialysis
    Dialysis
    Ankle Brachial Index
    Pulse Wave Analysis
    Electrocardiography
    Prospective Studies
    Baltimore
    Implantable Defibrillators
    Nails
    Population
    Cardiac Arrhythmias
    Cohort Studies
    Clinical Trials
    RNA
    DNA
    Serum

    Keywords

    • Arrhythmia
    • Dialysis
    • End stage renal disease
    • Hemodialysis
    • Mortality
    • Sudden cardiac death
    • Sudden death

    ASJC Scopus subject areas

    • Nephrology

    Cite this

    Parekh, R. S., Meoni, L. A., Jaar, B. G., Sozio, S. M., Shafi, T., Tomaselli, G. F., ... Kao, L. H. L. (Accepted/In press). Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study. BMC Nephrology. https://doi.org/10.1186/s12882-015-0050-4

    Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study. / Parekh, Rulan S.; Meoni, Lucy A.; Jaar, Bernard G.; Sozio, Stephen M.; Shafi, Tariq; Tomaselli, Gordon F.; Lima, Joao A.; Tereshchenko, Larisa; Estrella, Michelle M.; Kao, Linda H L.

    In: BMC Nephrology, 24.04.2015.

    Research output: Contribution to journalArticle

    Parekh, Rulan S. ; Meoni, Lucy A. ; Jaar, Bernard G. ; Sozio, Stephen M. ; Shafi, Tariq ; Tomaselli, Gordon F. ; Lima, Joao A. ; Tereshchenko, Larisa ; Estrella, Michelle M. ; Kao, Linda H L. / Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study. In: BMC Nephrology. 2015.
    @article{2156ddd913b44773a12c81268ea2dfd0,
    title = "Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study",
    abstract = "Background: Sudden cardiac death occurs commonly in the end-stage renal disease population receiving dialysis, with 25{\%} dying of sudden cardiac death over 5 years. Despite this high risk, surprisingly few prospective studies have studied clinical- and dialysis-related risk factors for sudden cardiac death and arrhythmic precursors of sudden cardiac death in end-stage renal disease. Methods/Design: We present a brief summary of the risk factors for arrhythmias and sudden cardiac death in persons with end-stage renal disease as the rationale for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study, a prospective cohort study of patients recently initiated on chronic hemodialysis, with the overall goal to understand arrhythmic and sudden cardiac death risk. Participants were screened for eligibility and excluded if they already had a pacemaker or an automatic implantable cardioverter defibrillator. We describe the study aims, design, and data collection of 574 incident hemodialysis participants from the Baltimore region in Maryland, U.S.A.. Participants were recruited from 27 hemodialysis units and underwent detailed clinical, dialysis and cardiovascular evaluation at baseline and follow-up. Cardiovascular phenotyping was conducted on nondialysis days with signal averaged electrocardiogram, echocardiogram, pulse wave velocity, ankle, brachial index, and cardiac computed tomography and angiography conducted at baseline. Participants were followed annually with study visits including electrocardiogram, pulse wave velocity, and ankle brachial index up to 4 years. A biorepository of serum, plasma, DNA, RNA, and nails were collected to study genetic and serologic factors associated with disease. Discussion: Studies of modifiable risk factors for sudden cardiac death will help set the stage for clinical trials to test therapies to prevent sudden cardiac death in this high-risk population.",
    keywords = "Arrhythmia, Dialysis, End stage renal disease, Hemodialysis, Mortality, Sudden cardiac death, Sudden death",
    author = "Parekh, {Rulan S.} and Meoni, {Lucy A.} and Jaar, {Bernard G.} and Sozio, {Stephen M.} and Tariq Shafi and Tomaselli, {Gordon F.} and Lima, {Joao A.} and Larisa Tereshchenko and Estrella, {Michelle M.} and Kao, {Linda H L}",
    year = "2015",
    month = "4",
    day = "24",
    doi = "10.1186/s12882-015-0050-4",
    language = "English (US)",
    journal = "BMC Nephrology",
    issn = "1471-2369",
    publisher = "BioMed Central",

    }

    TY - JOUR

    T1 - Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study

    AU - Parekh, Rulan S.

    AU - Meoni, Lucy A.

    AU - Jaar, Bernard G.

    AU - Sozio, Stephen M.

    AU - Shafi, Tariq

    AU - Tomaselli, Gordon F.

    AU - Lima, Joao A.

    AU - Tereshchenko, Larisa

    AU - Estrella, Michelle M.

    AU - Kao, Linda H L

    PY - 2015/4/24

    Y1 - 2015/4/24

    N2 - Background: Sudden cardiac death occurs commonly in the end-stage renal disease population receiving dialysis, with 25% dying of sudden cardiac death over 5 years. Despite this high risk, surprisingly few prospective studies have studied clinical- and dialysis-related risk factors for sudden cardiac death and arrhythmic precursors of sudden cardiac death in end-stage renal disease. Methods/Design: We present a brief summary of the risk factors for arrhythmias and sudden cardiac death in persons with end-stage renal disease as the rationale for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study, a prospective cohort study of patients recently initiated on chronic hemodialysis, with the overall goal to understand arrhythmic and sudden cardiac death risk. Participants were screened for eligibility and excluded if they already had a pacemaker or an automatic implantable cardioverter defibrillator. We describe the study aims, design, and data collection of 574 incident hemodialysis participants from the Baltimore region in Maryland, U.S.A.. Participants were recruited from 27 hemodialysis units and underwent detailed clinical, dialysis and cardiovascular evaluation at baseline and follow-up. Cardiovascular phenotyping was conducted on nondialysis days with signal averaged electrocardiogram, echocardiogram, pulse wave velocity, ankle, brachial index, and cardiac computed tomography and angiography conducted at baseline. Participants were followed annually with study visits including electrocardiogram, pulse wave velocity, and ankle brachial index up to 4 years. A biorepository of serum, plasma, DNA, RNA, and nails were collected to study genetic and serologic factors associated with disease. Discussion: Studies of modifiable risk factors for sudden cardiac death will help set the stage for clinical trials to test therapies to prevent sudden cardiac death in this high-risk population.

    AB - Background: Sudden cardiac death occurs commonly in the end-stage renal disease population receiving dialysis, with 25% dying of sudden cardiac death over 5 years. Despite this high risk, surprisingly few prospective studies have studied clinical- and dialysis-related risk factors for sudden cardiac death and arrhythmic precursors of sudden cardiac death in end-stage renal disease. Methods/Design: We present a brief summary of the risk factors for arrhythmias and sudden cardiac death in persons with end-stage renal disease as the rationale for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study, a prospective cohort study of patients recently initiated on chronic hemodialysis, with the overall goal to understand arrhythmic and sudden cardiac death risk. Participants were screened for eligibility and excluded if they already had a pacemaker or an automatic implantable cardioverter defibrillator. We describe the study aims, design, and data collection of 574 incident hemodialysis participants from the Baltimore region in Maryland, U.S.A.. Participants were recruited from 27 hemodialysis units and underwent detailed clinical, dialysis and cardiovascular evaluation at baseline and follow-up. Cardiovascular phenotyping was conducted on nondialysis days with signal averaged electrocardiogram, echocardiogram, pulse wave velocity, ankle, brachial index, and cardiac computed tomography and angiography conducted at baseline. Participants were followed annually with study visits including electrocardiogram, pulse wave velocity, and ankle brachial index up to 4 years. A biorepository of serum, plasma, DNA, RNA, and nails were collected to study genetic and serologic factors associated with disease. Discussion: Studies of modifiable risk factors for sudden cardiac death will help set the stage for clinical trials to test therapies to prevent sudden cardiac death in this high-risk population.

    KW - Arrhythmia

    KW - Dialysis

    KW - End stage renal disease

    KW - Hemodialysis

    KW - Mortality

    KW - Sudden cardiac death

    KW - Sudden death

    UR - http://www.scopus.com/inward/record.url?scp=84929438995&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84929438995&partnerID=8YFLogxK

    U2 - 10.1186/s12882-015-0050-4

    DO - 10.1186/s12882-015-0050-4

    M3 - Article

    JO - BMC Nephrology

    JF - BMC Nephrology

    SN - 1471-2369

    ER -